EPCAM and cancer: Strategies to enrich CTC from whole blood that are based on epithelial cell surface markers, like the one we used (CellSearch®: EpCAM and Cytokeratins 8, 18 and 19), have been reported by our group and others to also capture a minority of epithelial cells that harbor no apparent cancer‐driving genomic alterations, and which could in fact be normal epithelial cells [24].